عرض بسيط للتسجيلة

المرشدAl-Badriyeh, Daoud
المؤلفAl-Shaibi, Samaher Mohammad Ali
تاريخ الإتاحة2021-07-06T05:38:43Z
تاريخ النشر2021-06
معرّف المصادر الموحدhttp://hdl.handle.net/10576/21222
الملخصObjective: This thesis sought to evaluate the cost-effectiveness of oral paracetamol and intravenous (IV) indomethacin as alternatives to ibuprofen for patent ductus arteriosus (PDA) in neonates in Hamad Medical Corporation (HMC), Qatar. Methods: Decision-analytic, literature-based, economic simulation models were constructed, from the hospital perspective, to evaluate oral/IV ibuprofen versus IV indomethacin, and oral/IV ibuprofen versus oral paracetamol, as first-line therapies for PDA closure. Cost model inputs were HMC based, and therapy success was defined as PDA closure with/without adverse events. Results: Oral ibuprofen is dominant/cost-effective over IV indomethacin in 92% of simulated cases, but oral paracetamol was 82% dominant/cost-effective over oral ibuprofen. Against IV ibuprofen, IV indomethacin was 59% dominant/cost-effective, whereas oral paracetamol was dominant/cost-effective in 91% of the cases. Sensitivity analyses confirmed the study's robustness. Conclusion: For PDA closure, while IV indomethacin was cost-effective against IV ibuprofen, oral paracetamol was cost-effective against both oral and IV ibuprofen.
اللغةen
الموضوعIbuprofen
Indomethacin
Paracetamol
Patent Ductus Arteriosus
Neonates
Hamad Medical Corporation (HMC)
العنوانCost-effectiveness Analysis of Ibuprofen versus Indomethacin or Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates
النوعMaster Thesis
التخصصPharmacy
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة